Of these targets supported by literature to be involved in pancreatic cancer, 9/14 were previously implicated in gemcitabine resistance: NFKB2, AKT1, ZEB1, NFATC2, SHC1 and MUC1 modify gemcitabine resistance in pancreatic cancer, while ELK1 increases gemcitabine cytotoxicity in prostate cancer but has also been studied due to its transcription regulatory effect in pancreatic cancer. This evidence concerns the gene AKT1 and prostate cancer.